evelo biosciences inc news

What Makes Evelo Biosciences, Inc. (EVLO) a New Buy Stock

Story continues. Earnings Estimate Revisions for Evelo Biosciences, Inc. For the fiscal year ending December 2023, this company is expected to earn -$0.70 per share, which is a change of 46.6% ...

Evelo Biosciences Provides Clinical Updates | Evelo Biosciences

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced updates to its clinical programs. "In the fourth cohort of the …

News Release Details

CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, today announced positive data from its Phase 2 study evaluating EDP1815 versus placebo for the treatment …

News Release Details

CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, today presented preclinical data for EDP1867, a non-live pharmaceutical preparation of a single strain of ...

Evelo Biosciences, Inc. (EVLO) Latest Stock News & Headlines

Get the latest Evelo Biosciences, Inc. (EVLO) stock news and headlines to help you in your trading and investing decisions.

News Release Details

CAMBRIDGE, Mass. and LONDON, June 22, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologic therapies, announced today that EDP1815 will be included in the TACTIC-E clinical trial. The trial …

EVLO: Evelo Biosciences Inc Stock Price Quote

Stock analysis for Evelo Biosciences Inc (EVLO:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

News Release Details

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), ("Evelo" or the "Company") a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today reported financial results and business highlights …

Evelo Biosciences Presents New Preclinical Data for Anti-Tumor …

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) a clinical stage biotechnology company developing a new modality of orally delivered medicines which act in the small intestine with systemic effects, today announced preclinical data for EDP1908, its extracellular vesicle product candidate for the ...

Evelo Biosciences, Inc. Common Stock (EVLO) Stock Price, …

Evelo Biosciences, Inc. Common Stock (EVLO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Evelo Biosciences Announces Second Quarter Financial Results …

CAMBRIDGE, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), ("Evelo" or the "Company") a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced its second quarter 2023 financial ...

Evelo Biosciences, Inc. (EVLO) stock price, news, quote & history ...

Evelo Biosciences, Inc. (EVLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Evelo Biosciences Inc (EVLO) Price, News, History and Insights

Track Evelo Biosciences Inc (EVLO) price, historical values, financial information, and insights to empower your investing journey | MSN Money

EVLO | Evelo Biosciences Inc. Stock Price & News

View the latest Evelo Biosciences Inc. (EVLO) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Evelo Biosciences Announces Top-Line Results From its Phase 2 …

CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) ("Evelo" or the "Company"), a clinical stage biotechnology company …

Evelo Biosciences, Inc. (EVLO) Stock Price, News, Quote

Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study. Find the latest Evelo Biosciences, Inc. (EVLO) stock quote, history, news and other vital information to help you with your stock trading and investing.

Evelo Biosciences Announces Second Quarter Financial Results …

CAMBRIDGE, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), ("Evelo" or the "Company") a clinical stage biotechnology company …

SEC Filings | Evelo Biosciences

Quarterly Filings. 0001694665-23-000182.pdf. 0001694665-23-000182.rtf. 0001694665-23-000182.xls. EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML. The Investor Relations website contains information about Evelo Biosciences''s business for stockholders, potential investors, and financial analysts.

News Release Details

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), ("Evelo" or the "Company") a clinical stage biotechnology company …

Evelo Biosciences Announces $25.5 Million Private Placement

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation ...

Evelo Biosciences, Inc. Stock

DJ. TD Cowen Downgrades Evelo Biosciences to Market Perform From Outperform. 23-10-18. MT. Morgan Stanley Adjusts Evelo Biosciences'' Price Target to $10 From $2, Keeps Equalweight Rating. 23-07-26. MT. Chardan Downgrades Evelo Biosciences to Neutral From Buy, Cuts Price Target to $2.50 From $5. 22-11-16.

News Release Details

CAMBRIDGE, Mass., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company''s lead product in inflammation, detailing its mechanism …

Evelo Biosciences Announces $25.5 Million Private Placement | Evelo ...

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced that it has entered into a securities purchase agreement with …

Evelo Biosciences Announces Top-Line Results From its Phase 2 …

News for Evelo Biosciences; ... CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) ("Evelo" or the "Company"), a clinical stage biotechnology company ...

Evelo Biosciences Inc (EVLO) Stock Price & News

Get the latest Evelo Biosciences Inc (EVLO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Evelo Biosciences Inc (EVLO) Stock Price & News

Get the latest Evelo Biosciences Inc (EVLO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and...

News Release Details

CAMBRIDGE, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced it has entered into a senior secured loan agreement with Horizon Technology Finance …

Evelo Biosciences Announces Reverse Stock Split Effective

The reverse stock split will become effective at 5:00 p.m. Eastern Time today, June 29, 2023, after close of trading on The Nasdaq Global Select Market. The Company''s common stock is expected to ...

Evelo Biosciences Provides Clinical and Business Updates

CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis (SINTAX) today announced updates to its clinical pipeline as well as business updates.

Evelo Biosciences Announces Top-Line Results From its Phase 2 …

CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) ("Evelo" or the "Company"), a clinical stage biotechnology company developing a novel platform of ...

Evelo Biosciences, Inc. (EVLO) stock price, news, quote & history ...

Evelo Biosciences, Inc. (EVLO) OTC Markets EXMKT - OTC Markets EXMKT Delayed price. Currency in USD. Find the latest Evelo Biosciences, Inc. (EVLO) stock quote, history, news and other vital information to help you with your stock trading and investing.

News Release Details

CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today announced that it will host a conference call and live webcast at 8:30 a.m. …

Evelo Biosciences, Inc. (EVLO)

1 · Find the latest Evelo Biosciences, Inc. (EVLO) stock quote, history, news and other vital information to help you with your stock trading and investing.

Copyright © 2024.Nombre de la empresa Todos los derechos reservados. Mapa del sitio